



In 2008, Ipsogen reinforced its leadership in molecular diagnosis and monitoring of leukemia

During the last quarter of 2008, Ipsogen launched three new molecular diagnostic kits

Marseille, Jan. 12, 2009 - IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops and markets molecular diagnostic products for leukemia and breast cancer has launched 3 new products during the fourth quarter of 2008, that expand its leukemia molecular diagnostic portfolio:

- FusionQuant BCR-ABL IVD kit, used in the the detection and monitoring of chronic myeloid leukemias (CML), is a new CE marked expanded version of our existing product. The new IVD kit now provides all the necessary components in one package adding convenience and efficiency in the lab. The improved kit will also support the much needed test standardisation required for proper disease monitoring
- ProfileQuant CLLU1, in chronic lymphocytic leukemia (CLL). This research kit provides prognostic information, and has the potential to play a significant role in the monitoring of this disease.
- MutaScreen MPL, a research kit for the detection of MPL mutations in JAK2 negative myeloproliferative neoplasms (MPN), is a significant addition to the MPD family of products that Ipsogen offers.

These 3 new tests exemplify Ipsogen's strategy of (i) introducing technological and scientific innovation to address unmet diagnostic needs, and (ii) rapidly translating scientific discoveries into patient bedside tools, in line with the ultimate objective of enabling better and more personalised disease management.

"In the last quarter of 2008, we launched 3 new products. With 21 kits now in distribution, of which 10 are CE marked, Ipsogen's molecular diagnostic portfolio covers a significant range of the leukemia spectrum. These new products will help hematologists refine and improve treatment strategies" says Stephane Debono, COO and in charge of product planning.

Vincent Fert, CEO, concludes: *"These 3 new product launches are in line with our 2008 plans, and will further equip our sales staff with a comprehensive and market leading range of leukemia products that helps consolidate our leadership position in this growing market'.*

Next Press Release announcement - Full-year Sales 2008:

18 February 2009

(after market)



About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 48 people as of December 31, 2008. Its headquarters are located in Marseilles, France. The company has also a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: www.ipsogen.com

Contacts

IPSOGEN Vincent Fert

President and CEO
Tel.: + 33 (0)4 9129 3090
fert@ipsogen.com

Stanislas Piot

CFO
Tel.: + 33 (0)4 9129 3090
piot@ipsogen.com

ATCG Press Corporate and Product Information

Marielle Bricman
Tel.: + 33 (0)4 9125 0785

ipsogen@atcg-partners.com

NewCap Financial Communication and Investor Relations

Axelle Vuillermet & Pierre Laurent
Tel.: + 33 (0)1 44 71 94 93

ipsogen@newcap.fr